DNL-593
- Generic Name
- DNL-593
Denali and Takeda Open FTD-GRN Clinical Trial Site at UPenn
Denali Therapeutics and Takeda Pharmaceutical Company have initiated a phase 1/2 clinical trial for FTD caused by GRN mutations at the University of Pennsylvania, marking the first U.S.-based trial site. The study evaluates the safety and tolerability of DNL593, aiming to address progranulin deficits in FTD-GRN patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath